HCP (HCP) : 11 analysts are covering HCP (HCP) and their average rating on the stock is 3.48, which is read as a Hold. HCP (HCP) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. However, 3 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. 1 more analyst has given the stock a Sell recommendation. A total of 6 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
HCP (HCP) stock is expected to deviate a maximum of $6.08 from the average target price of $33 for the short term period. 7 Street Experts have initiated coverage on the stock with the most promising target being $43 and the most muted being $23.
Company shares have received an average consensus rating of Hold for the current week HCP (NYSE:HCP): The stock opened at $39.49 on Thursday but the bulls could not build on the opening and the stock topped out at $39.60 for the day. The stock traded down to $38.34 during the day, due to lack of any buying support eventually closed down at $38.56 with a loss of -2.38% for the day. The stock had closed at $39.50 on the previous day. The total traded volume was 4,229,031 shares.
In a related news, The Securities and Exchange Commission has divulged that Hsiao Kai, officer (Executive Vice President) of Hcp, Inc., had unloaded 266 shares at an average price of $36.04 in a transaction dated on May 9, 2016. The total value of the transaction was worth $9,587.
HCP, Inc. (HCP) is a real estate investment trust (REIT). The Company invests in real estate serving the healthcare industry in the United States. Its portfolio consists of investments in various healthcare segments: senior housing, post-acute/skilled nursing, life science, medical office and hospital. Its portfolio includes owned portfolio, unconsolidated joint ventures, and developments and redevelopments. Its owned portfolio includes around 1,040 properties under lease and 68 operating properties. It has interests in unconsolidated joint ventures representing around 88 properties in its senior housing, life science and medical office segments. It has assets under development, redevelopment and land held for future development in life science and medical office segments. The properties owned by it in medical office and senior housing segments, which are under development or redevelopment include Pacific Corporate Park, Memorial Hermann, Sky Ridge, Bayfront, Folsom and Deer Park.